110 results about "Lower total cholesterol" patented technology

The invention belongs to the technical field of affinal drug and diet formulas and new resource food, and particularly provides blood fat-reducing medical science formula food, specific medical formula food or non-specific medical formula food. The formula food is prepared by performing reasonable compatibility on multiple affinal drug and diet traditional Chinese medicines according to the traditional Chinese medicine essence theory and mixing drug-diet dual purpose traditional Chinese medicine extract essence extracted through a semi-bionic extraction method, multiple microencapsulated probiotics, oligopeptides extracted through biological enzymolysis, prebiotics, amino acid, carbohydrate, fat with a health-care function, multiple vitamins and mineral substances according to the requirements of a 'special medial-purpose formula food general rule' by combining the constitutive characters of hyperlipidemia patients; the formula food not only can serve as a single nutrition source to meet the nutritional requirement of the hyperlipidemia patients, but also achieves the effects of reducing total cholesterol, reducing serum triglyceride, reducing an atherosclerosis index, reducing blood pressure, reducing blood sugar, reducing fat to lose weight and enhancing the immunity.

Present invention features a novel use of Lactobacillus for treating type 2 diabetes, wherein the Lactobacillus is Lactobacillus reuteri GMNL-89 with the deposition numbers of BCRC 910340 and CCTCC M 207154 and comprises of live, dead bacteria or supernatant of the bacterial culture(s) and a pharmaceutically acceptable vehicle. The invention also discloses the efficacies of the indicated Lactobacillus strain including anti-oxidative enzyme activity, anti-inflammation, reduction of blood glucose level, reduction of triglycerides, reduction of total cholesterol, reduction of LDL, increase of HDL and improve insulin utilization.

Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microshperes encapsulating the exenatide.

A method for improving the bioavailability of a bioactive substance includes subjecting the bioactive substance to laser radiation. The laser radiation modifies the bioactive substance to thereby modify reactions relating thereto in the body. The method enables reductions in inflammation associated with autoimmune diseases, modification of reaction by-products in the body, increased homogenization and flattening of molecular shape and improved methylation. The improved methylation can be utilized to reduce homocysteine blood levels, and to reduce anxiety, depression, paranoia, hostility, somatization (perception of bodily distress) and obsessive-compulsive symptoms. Enhanced nitric oxide generation from modified L-arginine can be used to reduce systolic and diastolic blood pressure, lower total and LDL cholesterol levels, and improve the ratio of total to HDL cholesterol. Increased depth of penetration of sparse constructive nodes of laser radiation may increase the range of photodynamic therapy applications and a wide range of in vitro and in vivo modifications of molecular shape and activity. Laser acoustic resonance can be utilized to increase the homogeneity of crystals, or favor the generation of novel or preferred crystalline forms.

Aromatic-ring azacyclo derivatives and an application thereof are provided. The invention relates to compounds represented by the formula (V), and a preparation method and an application thereof in medicines. In particular, the invention relates to derivatives of the compounds represented by the general formula (V), and a preparation method and the application thereof as therapeutic agents in prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, type-II diabetes, hyperglycemia, obesity or insulin resistance syndromes and metabolic syndromes. The compounds disclosed by the invention also can reduce total cholesterol, LDL-cholesterol and triglycerides, increase the expression of hepatic LDL receptors and inhibit the expression of PCSK9.

The invention relates to a preparation method of a bitter gourd peptide arabinose composite tablet. The bitter gourd peptide arabinose composite tablet consists of the following components in parts by weight: 8-15 parts of bitter gourd polypeptides, 15-25 parts of L-arabinose, 0.1-0.3 part of chromium-enriched yeast, 25-35 parts of inulin, 5-15 parts of phytosterol, 10-15 parts of D- mannitol, 10-20 parts of microcrystalline cellulose, 0.5-1 part of magnesium stearate, and 2-5 parts of hydroxypropyl methylcellulose. The preparation method has beneficial effects that the bitter gourd peptide arabinose composite tablet is prepared by adopting a plurality of components beneficial to blood sugar control and blood lipid metabolism; compared with a way of independently adopting the bitter gourd polypeptides, the inulin or the phytosterol, and the like, a way of combining the bitter gourd polypeptides, the inulin or the phytosterol, and the like is better in effect, beneficial to blood sugar control and blood lipid metabolism of a patient with diabetes mellitus II, and free of influences on functions of livers and kidneys. Besides, the preparation method can improve sensibility of insulin better and can remarkably lower total cholesterol and low-density lipoprotein cholesterol of the patient with diabetes mellitus II.

The invention discloses a seafood soup stock comprising materials of, by weight: 1 to 3 particles of peeled shrimps, 1 to 3g of carrot, 2 to 4g of onion, 2 to 4g of crab meat stick, 1 to 3g of squid, 1.5g of parsley, 1.1g of common salt, 0.2g of a shrimp flavoring, 0.5g of chicken essence, 4g of eggs, 0.05g of pepper, 0.7g of maize starch, 0.8g of a seafood extract, 0.2g of a dried scallop extract, 0.2g of ginger, 0.16g of hydrolyzed vegetable protein, 0.5g of glucose, 0.9g of maltodextrin, and 0.03g of perilla oil. The seafood soup stock provided by the invention is advantaged in balanced nutrition, good color, good flavor, good taste, and food mouthfeel. The soup stock contains various nutrients, and provides positive effects and auxiliary therapeutic effects for human healthy. The alpha-linolenic acid contained in the soup stock is an unsaturated fatty acid assists in reducing blood fat, reducing blood pressure anticoagulation/thrombolysis, improving cardiovascular and cerebrovascular performances, reducing total cholesterol concentration, preventing cardiovascular diseases, inhibiting myocardial infarction and cerebral infarction, and preventing and inhibiting the forming of tumors. The soup stock is rich in trace elements such as calcium, phosphorous, iron, and magnesium. Therefore, the soup provides good heart protecting, hypoglycemic and cancer preventing effects. Also, the soup stock is beneficial for the strength and the hematogenesis functions of skeletons.

Nutritional fat or oil-based compositions for increasing HDL cholesterol, decreasing total cholesterol (TC), LDL cholesterol and decreasing the LDL/HDL cholesterol ratio in human plasma are described. The compositions can advantageously include at least 10% of myristic acid and/or lauric acid in which at least 3% of said fatty acid composition is myristic acid and at least 3% is lauric acid; in some cases at least 1% by weight myristic acid and/or lauric acid is esterified at the sn-2 position in triglyceride molecules. The compositions also include between 5% and 40% by weight linoleic acid, and typically further include at least 10% by weight monounsaturated fatty acids and between 15% and 55% by weight total saturated fatty acids. The sum of weight percentages for saturated, monounsaturated and polyunsaturated fatty acids equals 100%. In desirable cases, the composition is substantially cholesterol-free. Also described are fat compositions and diets which are adapted to limit increases in blood triglycerides, total cholesterol, LDL, and VLDL, even in the presence of dietary cholesterol.

A blood lipid lowering agent that functions through a same mechanism as berberine (e.g. berberine, one or more pharmacologically acceptable salts of berberine or a mixture thereof) and a blood lipid lowering agent that functions through a different mechanism than berberine (e.g. phytosterols, phytostanols, esters thereof or mixtures thereof) act synergistically to improve blood lipid profiles, for example, lowering total cholesterol, LDL-C or nonHDL-C, and triglyceride, and increasing the ratio of HDL-C to nonHDL-C. The two may be used in combination to treat or reduce the chance of contracting cardiovascular disease, hyperlipidemia, atherosclerosis, coronary heart disease, angina, cerebrovascular disease, stroke, overweight or obesity, diabetes, insulin resistance, hyperglycemia, hypertension, arrhythmia, diseases of the central nervous system, diseases of the peripheral nervous system and/or inflammation. The blood lipid lowering agent that functions through a same mechanism as berberine, with or without the blood lipid lowering agent that functions through a different mechanism than berberine, may also be used to control weight.

The invention belongs to the field of pharmacy, and relates to applications of leonurine in preparation of medicines used for treating atherosclerosis. Leonurine possesses a structure represented by formula (I). It is shown by results of experiments on a rabbit model with high fat diet induced atherosclerosis that, leonurine possesses anti-inflammatory activity and antioxidant activity, so that leonurine is capable of increasing the content of high-density lipoprotein, reducing the content of total cholesterol, reducing mean blood flow velocity of arteries, improving blood flowing states, protecting the integrity of blood vessel endothelium, and reducing deposition of lipid in blood vessels and generation of macrophage, and can be used for treating atherosclerosis.

The present invention relates to a compound as shown in a formula (VII), a preparation method and applications thereof in medicines. In particular, the present invention relates to a derivative of the compound as shown in the formula (VII), a preparation method, and the applications of the derivative used as a therapeutic agent in prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, II-type diabetes, hyperglycemia, obesity or insulin resistance syndrome and metabolic syndrome. The compound disclosed by the present invention can also reduce total cholesterol, LDL-cholesterol and triglyceride, and increases expression of a liver LDL receptor and decreases expression of PCSK9.

Compositions and methods are provided for using natural waxes or wax sub-fractions to maintain healthy blood lipid profiles, illustratively by lowering total cholesterol, lowering LDL-cholesterol, raising HDL cholesterol, and/or lowering triglyceride levels. Compositions and methods are also provided to treat symptoms of metabolic syndrome, including weight gain.

A composition and method for lowering total cholesterol levels and triglyceride levels and for reducing homocysteine levels in a human has policosanol, which is a mixture of fatty alcohols derived from sugar cane wax, omega fatty acids which are DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) and vitamins B6 (pyridoxine hydrochloride), B12 (cobalamin) and folic acid.

The invention discloses a method for preventing or treating conjunctivitis and herpes zoster palpebral dermatitis, bear gall powder used by the method, and a preparation method of the bear gall powder. The bear gall powder can be used for regulating blood lipid, lowering total cholesterol, preventing cardiovascular and cerebrovascular diseases and preventing atherosclerosis. Materials are subjected to ice crystallization during the preparation of the bear gall powder, and then freeze drying is performed to obtain the freeze-dried bear gall powder which can be called ice-crystalized bear gall powder. The Senbao ice-crystalized bear gall powder does not contain any auxiliary materials and chemical additives, can effectively regulate the blood lipid and lower the total cholesterol, can be effectively used for preventing cardiovascular and cerebrovascular diseases and atherosclerosis and preventing and treating solid tumor and blood system tumor, and can be particularly effectively used for preventing or treating the conjunctivitis and herpes zoster palpebral dermatitis.

The invention discloses bear gall powder capable of regulating blood fat, reducing cholesterol, and preventing cardiovascular and cerebrovascular diseases and atherosclerosis, a preparation method ofthe bear gall powder, and applications of the bear gall powder in preparation of products used for regulating blood fat, reducing total cholesterol, and preventing cardiovascular and cerebrovascular diseases and atherosclerosis. In the preparation process, material ice crystallization and freeze drying are adopted, so that the ice crystallized bear gall powder is obtained. No accessory ingredientor chemical additive is contained by a novel generation of Senbao bear gall powder. The ice crystallized bear gall powder is capable of regulating blood fat, reducing total cholesterol, and preventingcardiovascular and cerebrovascular diseases and atherosclerosis effectively.

The invention discloses application of dioscin in preparing a medicament for preventing and treating diabetes mellitus. According to the invention, the effects of dioscin in reducing blood-sugar content of various hyperglycemia models (I-type diabetes mellitus, II-type diabetes mellitus and acute hyperglycemia caused by adrenaline) and increasing the glycogen content of the hyperglycemia models are discovered, and the effects of the dioscin in improving the cell insulin resistance caused by high insulin, reducing contents of total cholesterol, triglyceride and low-density lipoprotein, increasing content of high-density lipoprotein and regulating fat metabolism disorder are simultaneously discovered, so that the application of the dioscin in preparing the medicament for preventing and treating the diabetes mellitus is invented. Various preparations prepared from the dioscin serving as a raw material according to pharmaceutically related requirement and clinical requirement can be applied clinically, and have the advantages of safety (no toxic or side effect), convenience, economy and the like.

The invention discloses a method for producing low-cholesterol eggs. According to the technical scheme, tea leaves and turmeric are boiled in water to make turmeric and tea leaf soup, and the turmeric and tea leaf soup is regularly drunk by laying chickens. The method has the advantages that: the tea pigment in the tea leaves can reduce the content of total cholesterol, and the turmeric can also reduce the content of the total cholesterol and improve the content of high-density cholesterol, so that the cholesterol content of the eggs can be greatly reduced after the laying chickens drink the turmeric and tea leaf soup, hypercholesterolemia can be greatly reduced after customers eat the eggs, cardiovascular disease is prevented, and the health quality of diets is improved.

The invention relates to a vegetable soup preparation, which comprises the following materials in part by weight: 4-5 parts of green vegetables, 2.5-3.5 parts of carrots, 2.5-3.5 parts of Chinese black mushrooms, 0.5-1.5 parts of chive, 5.5 parts of eggs, 0.3 part of vegetable extract, 0.4 part of chicken essence, 0.95 part of table salt, 0.25 part of hydrolyzed vegetable proteins, 0.1 part of mushroom extract, 0.1 part of ginger, 0.936 part of glucose, 0.936 part of corn starch, 0.9 part of maltodextrin, 0.02 part of pepper and 0.03 part of perilla herb oil. The vegetable soup preparation provided by the invention contains rich dietary fibers and minerals, not only can intestinal peristalsis be promoted, but also diseases can be prevented. Since the perilla herb oil is rich in alpha-linolenic acid, the vegetable soup preparation contributes to the reduction of blood fat, the reduction of blood pressure, anticoagulation, thrombolysis, the improvement of heart and brain blood vessels, the reduction of total cholesterol concentration, the prevention of cardiovascular diseases, the suppression of the occurrence myocardial infarction and cerebral infarction, the prevention and the suppression of the formation of tumors, the prevention of senile dementia, the restoration of eyesight and the improvement of learning memory. The vegetable soup preparation provided by the invention has the advantages that the nutrients are balanced, the color, fragrance and taste are good, and not only can the nutrients required by human bodies be provided, but also a certain curative effect is taken.

Belonging to the field of pharmacy, the invention relates to application of a Chinese prickly ash extract to preparation of medicaments for regulating cholesterol metabolism. In particular, the invention relates to regulation of cholesterol metabolism by a petroleum ether extract, an ethyl acetate extract and an n-butanol extract in high cholesterol and inflammation states. In vitro experiments show that in high cholesterol condition, the extracts can reduce the content of total cholesterol and secretion of an apolipoprotein B, inhibit the expression of related genes and proteins in a cholesterol biosynthesis pathway in cells, increase the expression of related genes or proteins in a reverse cholesterol transport process in cells. In vivo experiments prove that the ethyl acetate extract and n-butanol extract have anti-inflammatory activity, and improve the accumulation of inflammation-induced cholesterol in the liver by affecting expression of a liver X receptor-alpha and an ATP-binding cassette transporter gene 1. The invention further provides monomer (-)-syringaresinol-4-O-beta-D-glucoside isolated from the n-butanol extract and application thereof to regulation of cholesterol metabolism.

The invention discloses a health care food with an assistant blood fat reducing function. The health care food comprises the following components in percentage by weight: 35-90% of seabuckthorm seed oil, 1-30% of garlic oil, 0.5-30% of Ginkgo Leaf extract and 2-20% of auxiliary material. According to the health care food disclosed by the invention, the raw materials with definite effects can be scientifically mixed so that the effects of the product are ensured and the blood fat is reduced through reducing levels of total cholesterol and triglyceride and increasing the level of high density lipoprotein.